Latest News
Bristol-Myers Squibb Company
- Bristol Myers Squibb reports interim results for MS cell therapy By Investing.com
- Is One Older Drug The Biggest Risk To Bristol Myers Squibb Stock?
- Bristol Myers Squibb To Showcase Next-Generation Cancer Modalities And Leadership Across Solid Tumors At Esmo 2026
- Bristol Myers Squibb extends its longstanding commitment to cancer research through its C2C4C initiative
- Bristol Myers Squibb’s experimental lung disease drug meets key trial goal at lower dose
- Bristol Myers' lung disease drug succeeds at lower dose in late-stage trial
- IPF: Bristol Myers’ Experimental Drug Shows Promise Amid Limited Treatment Options
- Bristol Myers' drug improves lung function in late-stage trial
- Bristol Myers radiopharma cancer drug slows rare tumor progression in study
- Bristol Myers Stock Tumbles on ‘Confounding’ Trial Results
- Bristol Myers Squibb's admilparant hits primary endpoint in Phase 3 ALOFT-IPF trial
- Bristol Myers trial revisions shake confidence in new class of fibrosis drugs
Headlines from the last 30 days, linking to the original publishers. See all market news →